You are on page 1of 1

Please Join us


Wednesday, February 22, 2012

Searle Center, Seeley G. Mudd Building

Scientific Symposium
2:30 p.m. to 4:30 p.m.

Duke Cancer Institute: Contemporary Discoveries and Future Promise

Featured Speakers from the Duke Cancer Institute:
Sally Kornbluth, PhD; Vice Dean for Basic Science, School of Medicine, and James B. Duke Professor of Pharmacology and Cancer Biology Inhibition of Apoptosis and Resistance to Chemotherapy David Kirsch, MD, PhD; Associate Professor, Department of Radiation Oncology Consequences of Blocking the Tumor Suppressor p53 During Cancer Therapy in Mice Kimberly Blackwell, MD; Associate Professor, Department of Medicine Her2 Targeted Agents in Breast Cancer: Are We Close to Developing Drugs Better than Trastuzumab? Lee Jones, PhD; Associate Professor, Department of Radiation Oncology Exercise Therapy at the Intersection of Cardiovascular and Tumor Outcomes Following a Cancer Diagnosis


4:30 p.m. to 5:00 p.m.

Chancellors Lecture
5:00 p.m. to 6:00 p.m.
Charles L. Sawyers, MD

Overcoming Cancer Drug Resistance

Lasker~DeBakey Clinical Medical Research Award Winner Chair, Human Oncology and Pathogenesis Program, Memorial Sloan~Kettering Cancer Center

Victor J. Dzau, MD
Chancellor for Health Affairs Duke University

Michael B. Kastan, MD, PhD

Executive Director Duke Cancer Institute

Sponsored by the Duke University School of Medicine and Duke Cancer Institute. The Duke University School of Medicine designates this CME activity for a maximum of 3 AMA PRA Category 1 Credit(s) . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pre-registration is not required.